Connor Iapoce

Ocuphire's end-of-phase 2 meeting with the FDA supports APX3330's phase 3 advancement, with 3-step worsening in binocular DRSS score as the primary endpoint.

Real-world data from the FARETINA-AMD study show faricimab extended treatment intervals among eyes with nAMD.

Presented at AAO 2023, a new analysis indicates racial and ethnic minoritized individuals may have a higher likelihood of neovascular glaucoma.

Patients with HCV-related cirrhosis remain at risk for developing liver-related and non-liver-related events after achieving sustained virologic response.

Individuals with intermediate polysocial risk scores had a 1.2 times higher risk of developing psoriasis, while those with high polysocial risk scores had a 1.5 times higher risk.

Most ophthalmology teaching faculty noted their lack of awareness about available resources or training as a barrier, rather than a lack of time, perceived benefit, or funding.

At AAO 2023, Korobelnik provides insight into the efficacy and safety of aflibercept 8 mg in patients with nAMD observed over 2 years of the PULSAR study.

At AAO 2023, Kay shares insight into the topline results of the TEASE-1 study investigating the effect of gildeuretinol (ALK-001) on the inherited retinal disease.

The 3-year and 5-year renal survival rates did not exhibit significant changes, but IgAN's 10-year renal survival has shown gradual decreases since the 1990s.

New data shows one-quarter of patients with kidney disease associated with IBD progress to end-stage disease, with primary determinants including age and baseline eGFR.

Per the FDA, Kilitch Healthcare India Limited voluntarily recalls 27 eye drop items, including those distributed by CVS, Rite Aid, and Target, due to potential safety issues.

A post hoc analysis of the SCORED trial suggested the clinical benefit of sotagliflozin on heart failure and MACE-related outcomes in as early as 3 months in a high-risk population.

Presented at AHA 2023, new analyses of VOYAGER PAD suggest the benefit of rivaroxaban plus aspirin for high-risk and complex populations with PAD.

Christian Ruff, MD, MPH discusses results from the phase 2 AZALEA-TIMI 71 trial, the need for new antithrombotic therapies, and the net clinical benefit outcome of abelacimab for AF.

Sent on November 13, 2023, the FDA letter warns Amazon on the introduction of unapproved new eye drop products into interstate commerce on their website.

At AAO 2023, David Lally, MD describes results from the phase 2 ARCHER study and the potential benefit of intravitreal ANX007 for patients with GA.

Lowering blood pressure significantly reduced the risk of developing dementia among adults with hypertension in China compared to usual care.

The phase 2 KARDIA-1 study reports a single dose of zilebesiran safely reduced systolic blood pressure in people with mild-to-moderate hypertension for up to 6 months.

Presented at AHA 2023, the topline analysis of the phase 2 AZALEA-TIMI 71 trial showed abelacimab significantly reduced bleeding in people with Afib at risk of stroke, compared with rivaroxaban.

Phase 3 results from the GATHER2 trial show the treatment effect of avacincaptad pegol for geographic atrophy more than doubled over 2 years compared to year 1 of study.

Presented at AAO 2023, new data show dual Ang-2/VEGF-A inhibition with faricimab improved pigment epithelial detachment outcomes versus aflibercept.

In a pooled subcohort analysis of YOSEMITE and RHINE, faricimab showed comparable vision outcomes with fewer injections than aflibercept in DME eyes with baseline BCVA of ≤ 20/50.

Presented at AAO 2023, a retrospective study found no statistically significant difference in retinopathy worsening between GLP-1 RAs and SGLT2 inhibitors.

Six-month RIPPLE-1 results show treatment with the IBE-814 intravitreal implant led to CST reduction and BCVA improvement in patients with DME or RVO.

Presented at AAO 2023, first-time results suggest home OCT may have a significant effect on treatment burden in the management of nAMD.

First-year results from ALTITUDE suggest RGX-314 was well-tolerated and provided meaningful improvements in disease severity at dose levels 1 and 2.

On the floor at AAO 2023, host Veeral Sheth, MD, discusses UBX1325 for patients with diabetic macular edema, based on the 48-week results from the phase 2 BEHOLD study.

Presented at AAO 2023, new 3-year data from the GALE extension study shows increasing treatment effects over time with pegcetacoplan injection for geographic atrophy.

In a presentation at AAO 2023, Tsang discussed topline data from the phase 2 trial on MCO-010 optogenetic therapy for vision loss in Stargardt Disease.

Results from the phase 2/3 DIAMOND trial show a significant reduction in central macular thickness and significant visual gain in eyes treated with OCS-01 drops versus sham.